|
NALIRIFOX Clinical Trials
5 actively recruiting trials across 4 locations
Also known as: A combination of liposomal irinotecan,5 fluorouracil /leucovorin and oxaliplatin.
Pipeline
Phase 1: 2Phase 2: 1Phase 1/2: 2
Top Sponsors
- University of Kansas Medical Center1
- University of Colorado, Denver1
- UNC Lineberger Comprehensive Cancer Center1
- TheRas, Inc., d/b/a BBOT (BridgeBio Oncology Therapeutics)1
- Second Affiliated Hospital, School of Medicine, Zhejiang University1
Indications
- Cancer5
- KRAS G12S1
- Metastatic Non-Small Lung Cell Cancer1
- Advanced Lung Carcinoma1
- KRAS G12A1
Other1 trial
Los Angeles, California1 trial
BBO-11818 in Adult Subjects With KRAS Mutant Cancer
The Angeles Clinic and Research Institute - West Los Angeles Office
Phase 1
Aurora, Colorado1 trial
Intraperitoneal Paclitaxel With NALIRIFOX for Pancreatic Ductal Adenocarcinoma With Peritoneal Carcinomatosis
University of Colorado Cancer Center
Phase 1
Kansas City, Kansas1 trial
Onvansertib in Combination With NALIRIFOX for First Line Treatment of Advanced Pancreatic Cancer
The University of Kansas Cancer Center, Westwood Campus
Phase 1/2
Chapel Hill, North Carolina1 trial
Basal-like PDAC Treated With Gemcitabine, Erlotinib, and Nab-paclitaxel
University of North Carolina at Chapel Hill Lineberger Comprehensive Cancer Center
Phase 1/2
Trial data from ClinicalTrials.gov. Trial status and eligibility can change — verify directly with the study contact or on ClinicalTrials.gov.
This site does not provide medical advice. Always consult your doctor before considering enrollment in a clinical trial. Learn more on our About page.